T. Wilkinson (Southampton (Hampshire), United Kingdom), L. Kistemaker (Groningen, Netherlands)
Late Breaking Abstract - Activation of a murine skeletal muscle M3 muscarinic Designer Receptor Exclusively Activated by Designer Drug (DREADD) has cardiopulmonary consequences
S. Vincent (Kingston, Canada), D. Bone (Bethesda, United States of America), J. Wess (Bethesda, United States of America), J. Fisher (Kingston, Canada)
|   |
Late Breaking Abstract - Pigment epithelium-derived factor regulates cigarette-induced abnormal apoptosis of alveolar type II cells
L. Dai (Chengdu, Sichuan, China), T. Wang (Chengdu, Sichuan, China), L. Liu (Chengdu, Sichuan, China), J. Chen (Chengdu, Sichuan, China), F. Wen (Chengdu, Sichuan, China)
| |
Late Breaking Abstract - Ability of Hong Kong COPD patients to inhale dry powder inhaler
c. lee (Hong Kong, Hong Kong), V. Chan (Hong Kong, Hong Kong), P. Pang (Hong Kong, Hong Kong), S. Cheng (Hong Kong, Hong Kong), S. Tsui (Hong Kong, Hong Kong), P. Cheung (Hong Kong, Hong Kong), V. Chan (Hong Kong, Hong Kong), C. Chu (Hong Kong, Hong Kong)
| |
Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways
P. Rogliani (Rome, Italy), M. Matera (Naples, Italy), E. Puxeddu (Rome, Italy), F. Cavalli (Rome, Italy), F. Facciolo (Rome, Italy), M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy)
| |
Effects of a-1 antitrypsin augmentation therapy and a-1 antitrypsin deficiency in pneumococcal pneumonia in mice
L. Ostermann (Hannover, Germany), R. Maus (Hannover, Germany), J. Stolper (Hannover, Germany), L. Schütte (Hannover, Germany), F. Hollwedel (Hannover, Germany), S. Janciauskiene (Hannover, Germany), C. Mueller (Worcester, United States of America), T. Welte (Hannover, Germany), U. Maus (Hannover, Germany)
| |
Erythromycin inhibits neutrophil extracellular traps in smoking-related chronic pulmonary inflammation
H. Zhang (Nanning, China), S. Qiu (Nanning, China), Q. Tang (Nanning, China), X. Zhou (Nanning, China), J. Zhang (Nanning, China), Z. He (Nanning, China), J. Bai (Nanning, China), M. Li (Nanning, China), J. Deng (Nanning, China), Y. Liang (Nanning, China), X. Zhong (Nanning, China)
| |
Effect of photobiomodulation on reduction of CD4STAT4 and CD4IFN-? and increased treg cells and IL-10 in an experimental model of COPD.
A. De Brito Léia (São Paulo, Brazil), T. Santos (São Paulo, Brazil), K. Herculano (São Paulo, Brazil), N. Rigonato-Oliveira (São Paulo, Brazil), R. Palma (BARCELONA, Spain), . Franco (São Paulo, Brazil), K. Fernandes (São Paulo, Brazil), C. Alvarenga-Nascimento (São Paulo, Brazil), A. Ligeiro-Oliveira (São Paulo, Brazil)
| |
Effects of anti-IL-5 receptor alpha in an ex vivo 3D model of COPD
A. Benfante (Pa, Italy), A. Pitruzzella (Pa, Italy), A. Fucarino (Pa, Italy), F. Bucchieri (Pa, Italy), N. Scichilone (Pa, Italy)
| |
Relationship between pre-bronchodilator FEV1 and ex-vivo intrinsic tone in human small airways
F. Sanai (Sydney, Australia), A. Cairncross (Perth, Australia), P. Noble (Perth, Australia), J. Elliot (Perth, Australia), A. James (Perth, Australia), G. King (Sydney, Australia), B. Mcparland (Sydney, Australia)
| |
Bifidobacterium breve and Lactobacillus rhamnosus Attenuate the Inflammatory Mediators Secretion in a Human Bronchial Epithelial (BEAS) Cells Culture Stimulated with Cigarette Extract
M. Miranda (São José dos Campos, Brazil), A. Fialho (São José dos Campos, Brazil), R. Albertini (São José dos Campos, Brazil), A. Keller (São Paulo, Brazil), F. Aimbire (São José dos Campos, Brazil)
| |
Validation of sputum supernatant biomarker assays in stable and exacerbating COPD subjects
A. Mulvanny (Manchester, United Kingdom), C. Pattwell (Manchester, United Kingdom), J. Chomiak (Manchester, United Kingdom), T. Southworth (Manchester, United Kingdom), D. Singh (Manchester, United Kingdom)
| |
Bronchial Rheoplasty Increases Distal Airway Volume in Chronic Bronchitis
V. Kim (Philadelphia, United States of America), W. Krimsky (Baltimore, United States of America), B. Bannan (Menlo Park, United States of America), M. Machuca (Menlo Park, United States of America), W. Vos (Kontich, Belgium), J. De Backer (Kontich, Belgium), A. Valipour (Vienna, Austria), A. Ing (Sydney, Australia), J. Williamson (Sydney, Australia), T. Saghaie (Sydney, Australia), D. Steinfort (Melbourne, Australia), G. Snell (Melbourne, Australia), S. Fernandez-Bussy (Santiago, Chile), E. Dabscheck (Melbourne, Australia), L. Irving (Melbourne, Australia), S. Martel (Quebec, Canada), M. Fortin (Quebec, Canada), J. Waldstreicher (Menlo Park, United States of America)
| |
Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome
E. Blinova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation), I. Grebneva (Chelyabinsk, Russian Federation), O. Rodionova (Chelyabinsk, Russian Federation)
| |
Anti-interleukin 5 treatment in moderate to severe eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis
I. Tan (Manila, Philippines), R. Villalobos (Manila, Philippines), A. Jaen (Manila, Philippines), A. David-Wang (Manila, Philippines)
| |
Oral and inhalation usage of acetylcysteine in patients with COPD
G. Gumeniuk (Kiev, Ukraine), N. Kuzmenko (Kiev, Ukraine), O. Iaremenko (Kiev, Ukraine), D. Dobrianskiy (Kiev, Ukraine), R. Ilnytskyi (Kiev, Ukraine)
| |
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients
D. Singh (Manchester, United Kingdom), M. Govoni (Parma, Italy), M. Bassi (Parma, Italy), K. Beeh (Wesbaden, Germany), B. Colgan (Belfast, United Kingdom), O. Kornmann (Frankfurt, Germany), B. Laeker (London, United Kingdom), H. Watz (Grosshansdorf, Germany), G. Lucci (Parma, Italy), S. Geraci (Parma, Italy), E. Calabro Rocco (Parma, Italy), A. Emirova (Bois Colombes, France), M. Nandeuil (Bois Colombes, France)
| |